Adjuvant immunotherapy and targeted therapy for liver cancer after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining an immunotherapy drug (sintilimab) with a targeted therapy (lenvatinib) after surgical removal of liver cancer can help prevent the cancer from coming back. It is for patients whose tumors show a specific blood vessel pattern called VETC.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have not had any previous treatment for your liver cancer.
- Your liver function is well enough (Child-Pugh score of 7 or less).
- You are in good general health (ECOG score 0-1).
- Your cancer was completely removed by surgery (R0 resection) and confirmed as hepatocellular carcinoma.
- Your tumor shows a specific blood vessel pattern (VETC) on a special stain (CD34).
- You do not have other serious illnesses, infection, or recent bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments after liver cancer surgery to see which better prevents the cancer from coming back. You may be eligible if your surgery had a narrow margin and you have certain risk factors, like a tumor over 5 cm or high AFP levels.
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
This study tests whether giving focused local treatment (like radiation or surgery) after a combination of two drugs, sintilimab and lenvatinib, can help control advanced liver cancer that has spread to a few other places. The goal is to see if this approach can shrink tumors and possibly extend life.
This trial tests whether giving two medicines (an immunotherapy and a targeted therapy) after surgery can help prevent liver cancer from coming back in people with a specific type of tumor clot in the liver's main vein. If you've had surgery to remove the cancer and meet the health criteria, this treatment may lower your risk of recurrence.
This trial tests whether giving an immunotherapy drug (sintilimab) after surgery helps keep liver cancer with microscopic blood vessel invasion from coming back. It may improve chances of staying cancer-free after surgery.
This study tests a new approach: giving two immunotherapy drugs (sintilimab and ipilimumab) along with treatments that block blood flow to the tumor (TACE or ablation) before surgery for liver cancer that is at high risk of coming back. The goal is to see if this combination can shrink the tumor and reduce the chance of recurrence after surgery.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.